Image

Virus and Bronchial Epithelium in Children and the Elderly

Virus and Bronchial Epithelium in Children and the Elderly

Recruiting
17 years and younger
All
Phase N/A

Powered by AI

Overview

The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology that account for differences in the response and susceptibility to respiratory viruses. Epidemiology and cell-based data show that respiratory virus infections differentially affect children, adults or the elderly populations.

The current worldwide pandemic of SARS-CoV-2 clearly highlighted this notion with a large part of the deaths occurring in the elderly population and very few deaths amongst children. This may be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. Less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium (BE) such as rhinovirus (RV) and adenovirus (AdV) cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determine virus susceptibility and virus propagation.

Description

The objective of the VIRCHILLD project is to identify age-related modifications of the bronchial epithelium physiology able to explain differences in the response to respiratory viruses. Several epidemiological and cell-based data have demonstrated that respiratory virus infections differentially affect children, adults or the elderly populations. Perhaps, this difference has been put most notably into the spotlight by the current worldwide pandemic of SARS-CoV-2 with a large part of the deaths occurring in the elderly population whereas very few deaths amongst children have been recorded. According to some studies, this could be linked to a decreased transmission and/or viral load with SARS-CoV-2 in children compared to adults and elderly. What is less in the public eye is the observation that other major respiratory virus targeting the bronchial epithelium such as rhinovirus and adenovirus cause important clinical feature in children and have a much lower incidence in adults and the elderly populations, which is the opposite to the situation with SARS-CoV-2. Based on this remarkable discrepancy between respiratory viruses the investigators hypothesize that intrinsic age-controlled properties of the respiratory epithelium under resting physiological conditions determines virus susceptibility and virus propagation. Such hypothesis is supported by the literature and our own strong preliminary data. A highly complementing consortium composed of experts in lung physiology, pulmonary transcriptomic, respiratory viruses and ultrastructure analysis will address the question. The investigators will use three major respiratory pathogens (AdV, RV and SARS-CoV-2) to infect reconstituted fully functional respiratory epithelium obtained from children, adults and elderly and study parameters of virus infection and epithelial response. This project should highlight specific therapeutic targets against respiratory viruses with a high prevalence in children such as rhinovirus and adenoviruses to increase the therapeutic arsenal of clinician against those infections.

Eligibility

Inclusion Criteria:

For pediatric patients requiring research-specific bronchial brushing:

  • Child under 18 years old,
  • Requiring bronchoscopy as part of routine care
  • Having informed and signed consent from the holders of parental authority
        For pediatric patients whose bronchial brushing will be carried out as part of their care
        and for those whose surgical waste will be collected for research:
          -  Child under 18 years old,
          -  Requiring as part of routine care bronchoscopy and brushing or bronchial fibroscopy
             under general anesthesia or surgical resection/lobectomy
          -  Having expressed their non-opposition to their child's participation in research
        For adult patients:
          -  Man or woman
          -  Aged 18 or over
          -  Requiring as part of the care, thoracic surgery such as lobectomy, pneumonectomy or
             lung transplantation in the Thoracic Surgery Department of Haut Lévêque du Chu
             Hospital in Bordeaux or inclusion in the TUBE study, described below.
          -  having received an information note and not having objected to their participation in
             the research
        Exclusion Criteria:
          -  No affiliation or non-beneficiary of a social security system
          -  During a period of relative exclusion compared to another protocol
          -  Patient born before 36 weeks of amenorrhea
          -  Patient with a documented history of pulmonary fibrosis, primary pulmonary
             hypertension, cystic fibrosis, pulmonary malformation or chronic viral infections
             (hepatitis, HIV).
          -  Patient with any dental, nasopharyngeal or bronchial infection with fever (> 38°C)
             requiring systemic antibiotics in the previous 4 weeks

Study details
    SARS-CoV-2

NCT06224062

University Hospital, Bordeaux

29 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.